Praxis Precision Medicines rises as epilepsy drug cuts seizures in children

Praxis Precision Medicines

06/04/2026 14:12

** Shares of biotech firm Praxis Precision Medicines PRAX.O rise 4.7% to $325 premarket

** Co says its experimental drug elsunersen cut seizures in a rare form of childhood epilepsy; SCN2A-DEE is a genetic brain disorder that begins early in life and causes frequent, hard‑to‑treat seizures

** Co says early-stage study in nine children showed a 77% cut in monthly seizures versus placebo

** Says 71% of treated children saw seizures fall by more than half after six months, with benefits lasting up to a year

** Adds children also showed gains in sleep, movement, muscle tone and attention; no serious safety issues seen

** Says it is running a larger trial and will share more data at scientific meetings

** As of last close, stock up ~5% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))